Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cidara Therapeutics Inc (CDTX) has a current Price-to-Book (P/B) ratio of NaN. Compared to its 3-year average P/B ratio of 1.76 , the current P/B ratio is approximately NaN% higher. Relative to its 5-year average P/B ratio of 1.57, the current P/B ratio is about NaN% higher. Cidara Therapeutics Inc (CDTX) has a Forward Free Cash Flow (FCF) yield of approximately NaN%. Compared to its 3-year average FCF yield of -49.32%, the current FCF yield is approximately NaN% lower. Relative to its 5-year average FCF yield of -53.83% , the current FCF yield is about NaN% lower.
P/B
Median3y
1.76
Median5y
1.57
FCF Yield
Median3y
-49.32
Median5y
-53.83
Competitors Valuation Multiple
AI Analysis for CDTX
The average P/S ratio for CDTX competitors is 50.31, providing a benchmark for relative valuation. Cidara Therapeutics Inc Corp (CDTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CDTX
1Y
3Y
5Y
Market capitalization of CDTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CDTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CDTX currently overvalued or undervalued?
Cidara Therapeutics Inc (CDTX) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -4.32. The fair price of Cidara Therapeutics Inc (CDTX) is between to according to relative valuation methord.
What is Cidara Therapeutics Inc (CDTX) fair value?
CDTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cidara Therapeutics Inc (CDTX) is between to according to relative valuation methord.
How does CDTX's valuation metrics compare to the industry average?
The average P/S ratio for CDTX's competitors is 50.31, providing a benchmark for relative valuation. Cidara Therapeutics Inc Corp (CDTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Cidara Therapeutics Inc (CDTX) as of Jan 11 2026?
As of Jan 11 2026, Cidara Therapeutics Inc (CDTX) has a P/B ratio of NaN. This indicates that the market values CDTX at NaN times its book value.
What is the current FCF Yield for Cidara Therapeutics Inc (CDTX) as of Jan 11 2026?
As of Jan 11 2026, Cidara Therapeutics Inc (CDTX) has a FCF Yield of NaN%. This means that for every dollar of Cidara Therapeutics Inc’s market capitalization, the company generates NaN cents in free cash flow.
What is the current Forward P/E ratio for Cidara Therapeutics Inc (CDTX) as of Jan 11 2026?
As of Jan 11 2026, Cidara Therapeutics Inc (CDTX) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Cidara Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cidara Therapeutics Inc (CDTX) as of Jan 11 2026?
As of Jan 11 2026, Cidara Therapeutics Inc (CDTX) has a Forward P/S ratio of NaN. This means the market is valuing CDTX at $NaN for every dollar of expected revenue over the next 12 months.